retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide is drawing major attention
Pay in 4 interest-free payments of $6.80 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22

























![Time Vault (Retro) [30th Anniversary Edition] Timeless](https://cdn.shopify.com/s/files/1/0670/1927/6566/products/ce722fc2-7701-55f0-a6ce-b4315955d24e_569be513-7698-4920-8e9f-a7e282c1f7c6.jpg?v=1697056968)

